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Abstract 
Oral Disintegrating Tablets (ODTs) is a novel dosage form that can be dissolved on the tongue 
within 3min or less especially for geriatric and pediatric patients. Current ODT formulation studies 
usually rely on the personal experience of pharmaceutical experts and trial-and-error in the 
laboratory, which is inefficient and time-consuming.  The aim of current research was to establish 
the prediction model of ODT formulations with direct compression process by Artificial Neural 
Network (ANN) and Deep Neural Network (DNN) techniques. 145 formulation data were 
extracted from Web of Science. All data sets were divided into three parts: training set (105 data), 
validation set (20) and testing set (20). ANN and DNN were compared for the prediction of the 
disintegrating time. The accuracy of the ANN model has reached 85.60%, 80.00% and 75.00% on 
the training set, validation set and testing set respectively, whereas that of the DNN model was 
85.60%, 85.00% and 80.00%, respectively. Compared with the ANN, DNN showed the better 
prediction for ODT formulations. It is the first time that deep neural network with the improved 
dataset selection algorithm is applied to formulation prediction on small data. The proposed 
predictive approach could evaluate the critical parameters about quality control of formulation, 
and guide research and process development. The implementation of this prediction model could 
effectively reduce drug product development timeline and material usage, and proactively 
facilitate the development of a robust drug product. 
Keywords: oral disintegrating tablets; formulation prediction; artificial neural network; deep 
neural network; deep learning 
1. Introduction 
 
Oral dosage forms are always the most widely used dosage form because of their convenience 
of self-administration, good stability, accurate dosing and easy manufacturing[1]. However, 
swallowing difficulty of the pediatric or geriatric patient is a big concern for conventional tablets. 
Dysphagia is observed in about 35% of the general population among all age groups, as well as in 
up to 40% of the elder population and 18-22% of all patients in long-term care facilities[2]. To 
overcome the difficulty in swallowing, oral disintegrating tablets (ODTs) have been developed 
since the 1990s[3, 4]. ODTs are designed to be dissolved on the tongue rather than swallowed 
whole as conventional tablets [5, 6]. The disintegrating time of ODTs is within 3 min or less in the 
saliva without the intake of water [7, 8]. In recent years, there is the growing demand about good 
ODT formulations with new disintegrants and convenient preparation methods. There are three 
major techniques which are widely used for ODT manufacture: freeze drying, tablet molding, 
tablet compression [9, 10]. Comparing with many other preparation methods, direct compression 
is most widely used because of its most effective and simplest process[11]. The formulations of 
ODTs with direct compression method usually contain the filler, binder, disintegrant, lubricant and 
solubilizer[12]. Therefore, formulation design of ODTs is critical to minimize the disintegrating 
time with good tablet quality. 
Current pharmaceutical formulation development usually depends on experimental trial-and-
error by personal experiences of formulation scientists, which is inefficient and time-consuming. 
To improve the efficiency of formulation screening, the SeDeM diagram expert system was 
developed to optimize formulations[13]. SeDeM diagram expert system was able to evaluate the 
influence of every excipient on the final formulation for direct compression based on the 
experimental study and quantitative characterization parameters[14]. Then this expert system 
considered the type of excipients and physicochemical properties to output a recommended 
formulation. Moreover, the mathematical analysis of SeDeM was able to recommend not only 
formulation components but also the optimal ratios of excipients [14, 15]. Firstly, 43 excipients 
were investigated the suitability for direct compression, especially the compressibility of 
disintegrants. According to the ICHQ8, the suitability was described as these parameters: bulk 
density, tapped density, inter-particle porosity, Carr index, cohesion index, Hausner ratio, angle of 
repose, powder flow, loss on drying, hygroscopicity, particle size and homogeneity index. The 
SeDeM system could show the profile of every excipient and evaluate how suitable it can be used 
for direction compression[12]. According to the predicted result and combining with the 
experimental study, 8 excipients with the better properties were chosen to make a comparison 
using the new expert system. Compared with the old system, the new system could quantify the 
compressibility index of every excipient with the higher precision[16]. For example, ibuprofen 
ODT formulations were investigated with the suitability of 21 excipients and obtained the final 
SeDeM diagram with 12 parameters[17]. Current SeDeM method just focused on the 
recommended formulation, but it cannot quantitatively predict the disintegrating time of ODT 
formulations. With the challenge of pharmaceutical research, we need to establish a prediction 
method to assist experts evaluate the performance of ODT formulations. 
The neural network is a wonderful biologically-inspired model that learn from observational 
data. That is an artificial network with seriously connected units by simulating the neural structure 
of the brain[18]. Neural network has been applied to solve problems in many fields, such as voice 
recognition and computer vision. Artificial neural network and deep neural network are two widely 
used neural networks, as shown in Fig. 1&2 [19]. ANN is a simple neuron network with only one 
hidden layer, while DNN is a more powerful technique with many complex layers to reach the 
high-level data representation. In pharmacology and bioinformatics research, ANN also has been 
used over two decades, included prediction of protein secondary structure and quantitative 
structure-activity relationship[20]. As the pharmaceutical research, the prediction models were 
developed for break force and disintegration of tablet formulation by ANN, genetic algorithm, 
support vector machine and random forest approaches [21]. Another ANN example was 
quantitative structure activity relationships (QSAR) of antibacterial activity study[22, 23]. DNN 
is a type of representation learning with multiple levels of neural networks. Unlike the traditional 
ANN with manual feature extraction, deep-learning can automatically extract feature even 
transform low-level representation to more abstract level without any feature extractor [24]. 
Moreover, deep-learning is more sensitive to irrelevant and particular minute variations with 
complicated parameters of the network, which could reach higher accuracy rather than the 
conventional machine learning algorithms [19]. In recent years, DNN has been applied in 
pharmacy research, such as drug design, drug-induced liver injury and virtual screening[25]. In 
most cases, deep-learning could generate a novel and complex system to represent various objects 
through molecular descriptor so that it would be very helpful for drug discovery and prediction[26]. 
Junshui Ma et al. extracted data from internal Merck data and included on-target and absorption, 
distribution, metabolism, excretion (ADME), each molecular was described as serious features. 
Finally, they use deep neural nets to evaluate QSAR and the result was better than random forest 
commonly used[27].   
The aim of current research was to establish the quantitative prediction model of the 
disintegrating time of ODT formulations with direct compression process by ANN or DNN.  
 
2. Methodology 
 
2.1. Data Extraction 
  
Formulation data collection was the foundation of building the prediction model. To ensure 
the data reliability, the keyword search strategy was used in Web of Science database. The 
synonym strings of keywords were used, such as “oral” + “disintegrating” + “tablets” with 461 
results, “fast” + “disintegrating” + “tablets” with 407 results, “rapidly” + “disintegrating” + 
“tablets” with 266 results, and “oral” + “dispersible” + “tablets” with 84, respectively. Among 
these results, only research articles were selected for further data extraction. After the manual 
screening, 145 direct compressed ODT formulations with the disintegrating time were extracted 
including 23 active pharmacological ingredients (API) groups for our model, as shown in Table 1. 
All APIs were described as ten molecular parameters, including molecular weight, XLogP3, 
hydrogen bond donor count, hydrogen bond acceptor count, rotatable bond count, topological polar 
surface area, heavy atom count, complexity and logS. According to the function of excipients, all 
excipients were divided into five categories: filler, binder, disintegrant, lubricant, and solubilizer. 
Each type of excipients was individually coded for further training. The formulation data included 
API molecular descriptors and its amount, the type of encoded excipients and its amount, 
manufacture parameters (e.g. the hardness, friability, thickness and tablet diameter) and the 
disintegrating time of each formulation.  
 
2.2.Dataset Classification: Training set, Validation set and Testing set 
  
To ensure good prediction ability of computational model, especially in the small amount of 
pharmaceutical data, the dataset should be carefully divided into three parts, including training set, 
validation set and testing set. The three datasets strategy is an effective way to test the accuracy on 
new data out of our datasets. In details, the training set is for training model and the validation set 
is used for adjusting the parameters and finding the best model, while testing set shows the 
prediction accuracy on real unknown data from the datasets, as shown in Fig. 3. Therefore, how to 
select data for three datasets appropriately is the key step. Compared with random selection, 
manual selection and maximum dissimilarity algorithm selection, the improved maximum 
dissimilarity algorithm (MD-FIS) is the best choice. MD-FIS is based on the maximum 
dissimilarity algorithm considering with small group data in the whole dataset, it will avoid 
selecting data mostly from small group and ensure the representation of validation and test set. 
 
2.3. Hyperparameters of Artificial Neutral Network and Deep Neural Network 
   
The prediction model for ODTs was trained by ANN and DNN, respectively. In the training 
process, all data are normalized and then divided into three sets with our previous proposed MD-
FIS selection algorithm in R language. For ANN and DNN network, Deeplearning4j machine 
learning framework (https://deeplearning4j.org/) was used to train prediction models. All the 
source code can be found on the website (http://ml.mydreamy.net/pharmaceutics/ODT.html). The 
ANN model in Figure. 1. with termination condition at 15000 epochs and hidden nodes is 200. 
The deep-learning process in Figure. 2. use full-connected deep feedforward networks including 
ten layers with 2000 epochs. This neural network contains 50 hidden nodes on each layer. All 
networks choose tanh as the activation function except the last layer with sigmoid activation 
function. Learning rate is set to 0.01. Batch gradient descent with the 0.8 momentum is used for 
training the networks.  
Note that epoch indicates how many times the dataset is used for training. Feed-forward 
network means that the output of the network is computed layer-by-layer from one-direction 
without any inside loop. Learning rate impacts how fast the network will be convergent. Batch 
gradient descent is a training strategy to use all dataset to train the model at each time. Momentum 
indicates how much the speed will be kept in each training step. 
  
2.4. Pharmaceutical Evaluation Criterion 
 
European Pharmacopeia defined that ODT could disintegrate within 3 min in the mouth 
before being swallowed. In all our formulation data, the disintegrating time ranges from 0 sec to 
100 sec. Usually, the successful prediction in pharmaceutics is that absolute error is less than 10%. 
Thus, a good model is that the prediction deviation of the disintegrating time is not more than 
10sec. The accuracy of prediction disintegrating time is the percentage of successful prediction to 
total predictions:  !""#$!"%&'( = *#+,-$ ./ − . ≤ 104556$-78"98:;<  
Where, ./ is the prediction value, . is the label (real) value. All predictions are the number 
of predicted data. 
 
3. Results and discussion 
 
Fig. 4 showed the label (true) value and predictive value of disintegrating time on ANN model 
(A. training set; B. validation set; C. testing set), while indicated the true value and predictive value 
of disintegrating time on DNN model (D. training set; E. validation set; F. testing set). As shown 
in Figure. 4, the training set and validation set of both ANN and DNN showed good results. As 
Table 2 shows, the predictive accuracy of ANN model is 85.60% on training set and 80.00% on 
validation set, while the DNN model is 85.60% and 85.00%, respectively. However, the testing 
set of ANN with only 75.00% accuracy is lower than that of DDN (80.00%), which indicated that 
DNN is able to significantly better predict real unknown data than ANN.   
As the result shows, ANN is an efficient network for training prediction model within the 
adjustment of validation set, reaching a high accuracy on training set and validation set. However, 
when predicting real unknown data, the accuracy of testing set dropped significantly, which is 
called overfitting in machine learning. DNN performs well in all three data sets with over 80% 
accuracy and predicted stably with average value, which is more capable of establishing a better 
prediction model for ODT than ANN.  
When analyzing the different network structure between ANN and DNN, ANN just includes 
one hidden layer, while DNN includes ten layers with 2000 epochs and each layer contains 50 
hidden nodes. Thus, DNN could extract the feature of data with higher level and give a more 
accurate predictive result. It is unsurprised that DNN, as an innovative and effective technique for 
pharmaceutical research, can provide a higher accuracy prediction about disintegrating time than 
ANN. Thus, the desired DNN with the proposed MD-FIS selection algorithm can be used to 
achieve good predictive results on pharmaceutical formulations with small data.  
In order to ensure a satisfied prediction accuracy, two key factors are to be considered: data 
and algorithm. The first issue is the reliable data in pharmaceutical research. Deep-learning 
attempts to learn these characteristics to make better representations and create models from 
reliable data. Thus, data extraction is a critical step. In current research, reliable formulation data 
set were manually extracted and labeled from the research articles of Web of Science by 
experienced pharmaceutical scientists.  
On the other hand, small data in pharmaceutical research is the key issue to be solved. 
Although there are many DNN examples about imaging recognition, natural language processing 
and auto-mobile car, it is still very few pharmaceutical researches about deep-learning. Usually 
speaking, deep learning methods require a large amount of data for training. This is not a problem 
in other fields which have the big data source. However, this is a big challenge for the 
pharmaceutical researches due to the experimental limitation. Thus, the most important problem 
is: how to train a good prediction model on small data with high-dimensions input space? For 
example, the formulation data of ODTs includes the chemical and physical properties of APIs, 
multiple excipients with various ratios and four tablets characteristic parameters. In our 145-
formulation data, it was found that near half of APIs groups' size is less than 3 (small API group). 
Therefore, the splitting strategy of data set is critical for model establish.  Firstly, 20 representative 
testing set were picked up from the whole dataset by pharmaceutical scientists. As for training set 
and validation set selection, before using automatic selection algorithm, manual selection approach 
was adopted to ensure the appropriate selection of these two data sets. However, the manual 
selection needs experts with strong background knowledge, which is time-consuming and non-
standardized. When trying the random selection method, the data from small API groups with no 
representation was easily selected.  Thus, the improved maximum dissimilarity algorithm (MD-
FIS) is developed to select training set and validation set. MD-FIS is based on the maximum 
dissimilarity algorithm with the small group filter, representative initial set selection algorithm and 
new selection cost function. In the MD-FIS process, the data go through a filter to get rid of the 
data from the small API groups, then the MD-FIS randomly get the initial data sets, compute each 
distance from the initial data set to the corresponding remaining data, the minimum distance data 
are chosen as the final initial set. The final initial set and remaining data are the input to the 
dissimilarity algorithm with new selection cost function. The selected data is the validation set, 
while the remaining data is used as the training set. Because of the small group filter, the validation 
set from the general groups could represent the feature of whole data set.   
The second important issue is the selection of network algorithm. As deep convolutional 
networks inspired from visual neuroscience usually achieve a good result for processing images, 
video, speech and audio[28]. Recurrent neural networks contained history information of the 
sequence have brought the breakthrough in sequential data such as text and speech[29]. Our 
pharmaceutics data only includes properties of API, excipients with its amount and tablet 
parameters. There is no chronic relationship between each data. Our target is to predict the 
disintegrating time. Hence, compared with the deep convolutional networks and recurrent neural 
networks, the full-connected deep feedforward networks should be the best choice for the proposed 
problem. The challenge about deep feedforward network is computing too many parameters and 
vanishing the gradient. The results show that the satisfied accuracy could be reached by DNN. The 
deep learning method with the proposed data selection algorithms and pharmaceutics evaluation 
criterion can reach the desired models, which satisfy the accuracy requirements in the 
pharmaceutics. This deep-learning approach could save a lot of time, manpower and material 
resource for formulation development of ODTs. This will greatly benefit the formulation design 
in pharmaceutical research. 
Although DNN has reached the expected prediction accuracy on small pharmaceutical data 
sets, the mechanism of DNN is still a black box, and it is difficult to explain the mapping procedure 
from the input layer to the output layer. For example, it is unclear how each formulation component 
contributes to the disintegrating time. Moreover, current model cannot be directly applied to 
another evaluation parameters of formulations. Current prediction model for ODTs is just the first 
step in intelligent research for formulation development. Further research in intelligent formulation 
systems is underway in our laboratory.  
 
4. Conclusions 
 
The traditional “trial-and-error” method for formulation development has existed hundreds of 
years, which always cost a large amount of time, financial and human resources. Oral 
disintegrating tablets is a novel and important formulation form in recent years because of its 
convenience and good disintegration ability. Current research developed the DNN with MD-FIS 
select algorithm to establish a good prediction model for the disintegrating time of ODT 
formulations. On the other hand, this research is also a good example for deep-learning on small 
data. The proposed predictive approach not only contains formulation information of ODTs, but 
consider with the influence of tablet characteristic parameters, it could evaluate the critical 
parameters about quality control of formulation, and guide formulation research and process 
development. This deep-learning model could also be applied to other dosage forms and more 
fields in pharmaceutical research. The implementation of this prediction model could effectively 
reduce drug product development timeline and material usage, and proactively facilitate the 
development of a robust drug product.  
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Figure and Table legends 
  
Fig. 1. The network structure of ANN. 
Fig. 2. The network structure of DNN. 
Fig. 3. The flowchart of training model. 
Fig. 4. The true value and predictive value on dataset: (A) the true value and predictive value of 
training set, (B) validation set and (C) testing set on ANN model; (D) the true value and 
predictive value of training set, (E) validation set and (F) testing set on DNN model.    
 
 
Table 1 The formulation data of ODTs 
Table 2 The accuracies of OFDT on training, testing, and final testing sets 
  
 
Figures: 
 
 
 
  Fig. 1. The network structure of ANN  
 
 
  Fig. 2. The network structure of DNN  
 
 
 
Fig. 3. The flowchart of establishing model   
  
 
  
Fig. 4. The true value and predictive value on dataset: (A) the true value and predictive value of 
training set and (B) validation set and (C) testing set on ANN model. (D) the true value and 
predictive value of training set and (E) validation set and (F) testing set on DNN model. 
 
 
 
Tables: 
Table 1 The formulation data of ODTs 
API Filler Binder Disintegrant Lubricant Solubilzer           
API Dose (mg) Filler 
Dose 
(mg) Filler 
Dose 
(mg) 
Bind
er 
Dose 
(mg) 
Disinteg
rant 
Dose 
(mg) 
Disinteg
rant 
Dose 
(mg) 
Lubrican
t 
Dose 
(mg) 
Lubrican
t 
Dose 
(mg) Solubilzer 
Dose 
(mg) 
Hardnes
s (N) 
Friability
(%) 
Thicknes
s (mm) 
Punch 
(mm) 
Disintegrati
on time 
(sec) 
Mirtazapine  45 Mannitol 285 MCC 0 PVP 195 CC-Na 25    Aerosil  0 
Mg 
stearate 10     53 0.56 4.76  30 
Mirtazapine  45 Mannitol 264 MCC 0 PVP 195 CC-Na 25    Aerosil  0 
Mg 
stearate 10     50 0.52 4.75  24 
Hydrochlorothia
zide 50 
Sucralo
se 133.6        CC-Na 8 PVPP 8 Aerosil  15 
Mg 
stearate 4     45   8 10 
Hydrochlorothia
zide 50 
Sucralo
se 0        CC-Na 8 PVPP 8 Aerosil  15 
Mg 
stearate 4     45   8 21 
Paracetamol 224.4 Mannitol 303.6        CC-Na 44.4    
Mg 
stearate 3        28 2.06  11 37 
Paracetamol 224.4 Mannitol 303.6        CC-Na 36.6    
Mg 
stearate 3        41 0.88  11 58 
Paracetamol 224.4 Mannitol 291.6        CC-Na 32.4    
Mg 
stearate 3        48 0.56  11 40 
Paracetamol 224.4 Mannitol 291.6        CC-Na 28.6    
Mg 
stearate 3        50 0.65  11 67 
Paracetamol 325 MCC 113        CC-Na 0 CMS-Na 40 
Mg 
stearate 2        45 0.86  11 37 
Paracetamol 325 MCC 113        CC-Na 40 CMS-Na 20 
Mg 
stearate 2        45 0.69  11 52.33 
Famotidine 20 Mannitol 71.76 
Lacto
se 0 
L-
HPC 0 CC-Na 2.34 
CMS-
Na 0 
Mg 
stearate 0.5        46 0.95  7 22.91 
Famotidine 20 Mannitol 0 
Lacto
se 71.6 
L-
HPC 0 CC-Na 2.34 
CMS-
Na 0 
Mg 
stearate 0.5        65 0.96  7 11.69 
Famotidine 20 Mannitol 0 
Lacto
se 0 
L-
HPC 0 CC-Na 2.34 
CMS-
Na 0 
Mg 
stearate 0.5        60 1.25  7 14.63 
Famotidine 20 Mannitol 75.66 
Lacto
se 0 
L-
HPC 0 CC-Na 0 
CMS-
Na 6.24 
Mg 
stearate 0.5        57 0.99  7 17.19 
Famotidine 20 Mannitol 0 
Lacto
se 75.66 
L-
HPC 0 CC-Na 0 
CMS-
Na 6.24 
Mg 
stearate 0.5        92 1.02  7 30.27 
Famotidine 20 Mannitol 0 
Lacto
se 0 
L-
HPC 0 CC-Na 0 
CMS-
Na 6.24 
Mg 
stearate 0.5        103 0.98  7 12.48 
Famotidine 20 Mannitol 66.3 
Lacto
se 0 
L-
HPC 11.7 CC-Na 0 
CMS-
Na 0 
Mg 
stearate 0.5        55 0.97  7 11.42 
Famotidine 20 Mannitol 0 
Lacto
se 66.3 
L-
HPC 11.7 CC-Na 0 
CMS-
Na 0 
Mg 
stearate 0.5        108 1.13  7 47.25 
Famotidine 20 Mannitol 0 
Lacto
se 0 
L-
HPC 11.7 CC-Na 0 
CMS-
Na 0 
Mg 
stearate 0.5        121 0.92  7 52.21 
Acetaminophen 325 MCC 133        CC-Na 20 CMS-Na 0 
Mg 
stearate 2        45 0.86  11.1 33 
Acetaminophen 325 MCC 113        CC-Na 40 CMS-Na 0 
Mg 
stearate 2        46 0.43  11.1 35 
Acetaminophen 325 MCC 113        CC-Na 20 CMS-Na 0 
Mg 
stearate 2        45 0.76  11.1 24 
Acetaminophen 325 MCC 133        CC-Na 0 CMS-Na 20 
Mg 
stearate 2        47 0.92  11.1 42.33 
Acetaminophen 325 MCC 113        CC-Na 0 CMS-Na 20 
Mg 
stearate 2        50 0.95  11.1 29 
Acetaminophen 325 MCC 133        CC-Na 20 CMS-Na 20 
Mg 
stearate 2        52 0.78  11.1 51 
Acetaminophen 325 MCC 113        CC-Na 20 CMS-Na 20 
Mg 
stearate 2        46 0.67  11.1 53.33 
Olanzapine 11.8 Mannitol 41 MCC 61.45     CC-Na 14    
Mg 
stearate 0.875 Aerosil  0.875 
2-hydroxypropyl-β-
cyclodextrin 43 36 0.78 3.13 8 27 
Olanzapine 11.8 Mannitol 41 MCC 59.7     CC-Na 15.75    
Mg 
stearate 0.875 Aerosil  0.875 
2-hydroxypropyl-β-
cyclodextrin 43 35 0.82 3.18 8 25 
Olanzapine 11.8 Mannitol 41 MCC 57.95     CC-Na 17.5    
Mg 
stearate 0.875 Aerosil  0.875 
2-hydroxypropyl-β-
cyclodextrin 43 33 0.87 3.34 8 20 
Olanzapine 11.8 Mannitol 41 MCC 70.2     CC-Na 5.25    
Mg 
stearate 0.875 Aerosil  0.875 
2-hydroxypropyl-β-
cyclodextrin 43 33 0.85 3.13 8 25 
Olanzapine 11.8 Mannitol 41 MCC 68.45     CC-Na 7    
Mg 
stearate 0.875 Aerosil  0.875 
2-hydroxypropyl-β-
cyclodextrin 43 36 0.85 3.26 8 25 
Olanzapine 11.8 Mannitol 41 MCC 70.2     CC-Na 0    
Mg 
stearate 0.875 Aerosil  0.875 
2-hydroxypropyl-β-
cyclodextrin 43 36 0.85 3.14 8 55 
Olanzapine 11.8 Mannitol 41 MCC 68.45     CC-Na 0    
Mg 
stearate 0.875 Aerosil  0.875 
2-hydroxypropyl-β-
cyclodextrin 43 34 0.86 3.14 8 26 
Olanzapine 11.8 Mannitol 41 MCC 70.2     CC-Na 5.25    
Mg 
stearate 0.875 Aerosil  0.875 
2-hydroxypropyl-β-
cyclodextrin 43 35 0.82 3.76 8 28 
Olanzapine 11.8 Mannitol 41 MCC 68.45     CC-Na 7    
Mg 
stearate 0.875 Aerosil  0.875 
2-hydroxypropyl-β-
cyclodextrin 43 32 0.79 3.64 8 21 
Olanzapine 11.8 Mannitol 41 MCC 66.7     CC-Na 8.75    
Mg 
stearate 0.875 Aerosil  0.875 
2-hydroxypropyl-β-
cyclodextrin 43 35 0.52 3.23 8 22 
Olanzapine 11.8 Mannitol 41 MCC 70.2     CC-Na 5.25    
Mg 
stearate 0.875 Aerosil  0.875 
2-hydroxypropyl-β-
cyclodextrin 43 35 0.75 3.25 8 31 
Olanzapine 11.8 Mannitol 41 MCC 68.45     CC-Na 7    
Mg 
stearate 0.875 Aerosil  0.875 
2-hydroxypropyl-β-
cyclodextrin 43 32 0.67 3.25 8 27 
Olanzapine 11.8 Mannitol 41 MCC 66.7     CC-Na 8.75    
Mg 
stearate 0.875 Aerosil  0.875 
2-hydroxypropyl-β-
cyclodextrin 43 38 0.65 3.21 8 68 
Eslicarbazepine 800 Mannitol 150 MCC 70.08     CC-Na 0 PVPP 40 
Mg 
stearate 4    β-cyclodextrin 109.9 38 0.85 6.5 16 45.33 
Eslicarbazepine 800 Mannitol 150 MCC 50.08     CC-Na 0 PVPP 60 
Mg 
stearate 4    β-cyclodextrin 109.9 37 0.75 6.5 16 24.66 
Eslicarbazepine 800 Mannitol 150 MCC 70.08     CC-Na 0 PVPP 0 
Mg 
stearate 4    β-cyclodextrin 109.9 38 0.81 6.5 16 49.33 
Eslicarbazepine 800 Mannitol 150 MCC 50.08     CC-Na 0 PVPP 0 
Mg 
stearate 4    β-cyclodextrin 109.9 38 0.87 6.5 16 55.66 
Eslicarbazepine 800 Mannitol 150 MCC 70.08     CC-Na 0 PVPP 0 
Mg 
stearate 4    β-cyclodextrin 109.9 37 0.72 6.5 16 57.33 
Eslicarbazepine 102 Mannitol 150 MCC 50.08     CC-Na 0 PVPP 60 
Mg 
stearate 4    β-cyclodextrin 109.9 38 0.72 6.5 16 24.66 
Eslicarbazepine 102 Mannitol 150 MCC 70.08     CC-Na 40 PVPP 0 
Mg 
stearate 4    β-cyclodextrin 109.9 38 0.81 6.5 16 61.66 
Lornoxicam 4 Mannitol 63.5 MCC 15 
L-
HPC 3 CC-Na 7.5    
Mg 
stearate 1 Aerosil  1 
Cyclodextrin 
Methacrylate 0 24 0.42 2.14 12 7.4 
Lornoxicam 4 Mannitol 63.5 MCC 15 
L-
HPC 3 CC-Na 7.5    
Mg 
stearate 1 Aerosil  1 
Cyclodextrin 
Methacrylate 4 22 0.28 2.22 12 7.3 
Lornoxicam 4 Mannitol 63.5 MCC 15 
L-
HPC 3 CC-Na 7.5    
Mg 
stearate 1 Aerosil  1 
Cyclodextrin 
Methacrylate 12.21 23 0.36 2.21 12 7.4 
Meloxicam 7.5 Mannitol 20 MCC 40     PVPP 10    
Mg 
stearate 1        27 0.99 2.03 9.58 46.17 
Miconazole 
nitrate 56.5 
Mannit
ol 58 MCC 58 
HPM
C 4.7 CC-Na 4.8    
Mg 
stearate 0 SDS 18     56 0.45 3.53 8 40 
Miconazole 
nitrate 56.5 
Mannit
ol 78 MCC 26 
HPM
C 4.7 CC-Na 0    
Mg 
stearate 0 SDS 24     66 0.67 3.02 8 35 
Miconazole 
nitrate 56.5 
Mannit
ol 58 MCC 58 
HPM
C 4.7 CC-Na 14.4    
Mg 
stearate 6 SDS 0     79 0.18 3.52 8 18 
Dextromethorph
an  15 
Mannit
ol 10 MCC 25                     37 0.76 3.64 9.53 21 
Dextromethorph
an  15 
Mannit
ol 10 MCC 25                     40 0.74 3.56 9.53 13.8 
Risperidone 0.5 Mannitol 1.3 MCC 2.6 PVP 0 CC-Na 0 
CMS-
Na 0.5 Aerosil  50          1.58 3 14.83 
Risperidone 0.5 Mannitol 1.3 MCC 2.6 PVP 0.5 CC-Na 0 
CMS-
Na 0 Aerosil  50          1.65 3 12.97 
Risperidone 0.5 Mannitol 2.6 MCC 1.3 PVP 0 CC-Na 0.5 
CMS-
Na 0 Aerosil  50          1.65 3 2.99 
Risperidone 0.5 Mannitol 2.6 MCC 1.3 PVP 0 CC-Na 0 
CMS-
Na 0.5 Aerosil  50          1.66 3 4.39 
Risperidone 0.5 Mannitol 1.45 MCC 1.45 PVP 0 CC-Na 0 
CMS-
Na 0.5 Aerosil  50          1.64 3 15.91 
Risperidone 0.5 Mannitol 2.6 MCC 1.3 PVP 0.5 CC-Na 0 
CMS-
Na 0 Aerosil  50          1.63 3 1.68 
Risperidone 0.5 Mannitol 2.6 MCC 1.3 PVP 0.5 CC-Na 0 
CMS-
Na 0 Aerosil  50          1.77 3 2.19 
Risperidone 0.5 Mannitol 1.3 MCC 2.6 PVP 0 CC-Na 0.5 
CMS-
Na 0 Aerosil  50          1.67 3 8.01 
Risperidone 0.5 Mannitol 1.3 MCC 2.6 PVP 0.5 CC-Na 0 
CMS-
Na 0 Aerosil  50          1.61 3 3.93 
Risperidone 0.5 Mannitol 1.45 MCC 1.45 PVP 0 CC-Na 0 
CMS-
Na 0.5 Aerosil  50          1.63 3 9.17 
Risperidone 0.5 Mannitol 1.45 MCC 1.45 PVP 0.5 CC-Na 0 
CMS-
Na 0 Aerosil  50          1.65 3 2.41 
Risperidone 0.5 Mannitol 1.45 MCC 1.45 PVP 0.5 CC-Na 0 
CMS-
Na 0 Aerosil  50          1.6 3 2.61 
Risperidone 0.5 Mannitol 1.45 MCC 1.45 PVP 0.5 CC-Na 0 
CMS-
Na 0 Aerosil  50          1.63 3 2.81 
Granisetron 50 Mannitol 20 MCC 55     CC-Na 0 
CMS-
Na 5 Aerosil  2 
Mg 
stearate 1.5     35 0.2 4.38 6 35 
Granisetron 50 Mannitol 20 MCC 52.5     CC-Na 0 
CMS-
Na 7.5 Aerosil  2 
Mg 
stearate 1.5     40 0.13 4.31 6 30 
Granisetron 50 Mannitol 20 MCC 55     CC-Na 5 
CMS-
Na 0 Aerosil  2 
Mg 
stearate 1.5     45 0.14 4.39 6 32 
Granisetron 50 Mannitol 20 MCC 52.5     CC-Na 7.5 
CMS-
Na 0 Aerosil  2 
Mg 
stearate 1.5     35 0.13 4.37 6 28 
Granisetron 50 Mannitol 20  52.5     CC-Na 0 
CMS-
Na 0 Aerosil  2 
Mg 
stearate 1.5     30 0.21 4.34 6 22 
Mefenamic 100 MCC 81.75        PVPP 32.5    Aerosil  32.5 Mg stearate 3.25     18 0.92 4.1 12 25 
Mefenamic 100 MCC 181.75        PVPP 32.5    Aerosil  32.5 
Mg 
stearate 3.25     22 0.65 3.8 12 25 
Atorvastatin 10 Mannitol 175    
L-
HPC 15 CC-Na 15    
Mg 
stearate 1.2            30 
Atorvastatin 10 Mannitol 182.6    
L-
HPC 15 CC-Na 15    
Mg 
stearate 1.2            30 
Montelukast 5.2 Mannitol 70 MCC 48.8     PVPP 20    
Mg 
stearate 2    Sodium Bicarbonate 0 140 0.06 3.79  40 
Montelukast 5.2 Mannitol 0 MCC 116.8     PVPP 20    
Mg 
stearate 2    Sodium Bicarbonate 16 97 0.11 3.78  10 
Montelukast 5.2 Mannitol 0 MCC 116.8     PVPP 6    
Mg 
stearate 2    Sodium Bicarbonate 16 93 0.04 3.07  15 
Montelukast 5.2 Mannitol 0 MCC 92.41     PVPP 4.8    
Mg 
stearate 1.596    Sodium Bicarbonate 12.80 158 0.17 3.79  8 
Montelukast 5.2 Mannitol 0 MCC 133.1     PVPP 6.8    
Mg 
stearate 2.261    Sodium Bicarbonate 18.14 103 0.08 3.74  35 
Montelukast 5.2 Mannitol 0 MCC 110.8     PVPP 6    
Mg 
stearate 2    Sodium Bicarbonate 22.01 85 0.06 3.77  5 
Montelukast 5.2 Mannitol 0 MCC 113.8     PVPP 9    
Mg 
stearate 2    Sodium Bicarbonate 16 87 0.06 3.76  10 
Amlodipine 5 Mannitol 25 MCC 40     PVPP 40    
Mg 
stearate 2 SDS 1     29 0.12 4.06 9 19.8 
Nisoldipine 50 Mannitol 70 MCC 58 PVP 40 CC-Na 10 PVPP 10 
Mg 
stearate 2         0.44  8 36 
Nisoldipine 50 Mannitol 70 MCC 58 PVP 0 CC-Na 10 PVPP 10 
Mg 
stearate 2         0.67  8 30 
Nisoldipine 50 Mannitol 70 MCC 98     CC-Na 10 PVPP 10 
Mg 
stearate 2         0.52  8 90 
Donepezil 10 Mannitol 170.1        CC-Na 0 PVPP 56 
Mg 
stearate 3        54 0.87 4.12 9.5 11 
Donepezil 10 Mannitol 198.1        CC-Na 0 PVPP 28 
Mg 
stearate 3        59 0.62 4.14 9.5 15 
Donepezil 10 Mannitol 170.1        CC-Na 0 PVPP 0 
Mg 
stearate 3        67 0.43 4.11 9.5 38 
Donepezil 10 Mannitol 170.1        CC-Na 56 PVPP 0 
Mg 
stearate 3        55 0.52 4.12 9.5 7.11 
Donepezil 10 Mannitol 198.1        CC-Na 0 PVPP 0 
Mg 
stearate 3        69 0.57 4.12 9.5 73 
Donepezil 10 Mannitol 170.1        CC-Na 0 PVPP 56 
Mg 
stearate 3        54 0.87 4.12 9.5 11 
Lamotrigine 25 Mannitol 47.05        PVPP 2.5    
Mg 
stearate 0.75        40 0.84  5 17.21 
Lamotrigine 25 Mannitol 44.25        PVPP 5    
Mg 
stearate 0.75        40 0.27  5 12.33 
Lamotrigine 25 Mannitol 44.25        PVPP 5    
Mg 
stearate 0.75        10 1.03  5 3.72 
Lamotrigine 25 Mannitol 45.25        PVPP 3.75    
Mg 
stearate 1        10 1.52  5 4.04 
Lamotrigine 25 Mannitol 45.75        PVPP 3.75    
Mg 
stearate 0.5        10 1.36  5 3.47 
Lamotrigine 25 Mannitol 45.25        PVPP 3.75    
Mg 
stearate 1        40 0.42  5 17.17 
Lamotrigine 25 Mannitol 56.5        PVPP 2.5    
Mg 
stearate 1        25 2.1  5 8 
Lamotrigine 25 Mannitol 44.5        PVPP 5    
Mg 
stearate 0.5        25 0.68  5 5.85 
Lamotrigine 25 Mannitol 45.75        PVPP 3.75    
Mg 
stearate 0.5        40 0.64  5 10.5 
Lamotrigine 25 Mannitol 46.5        PVPP 2.5    
Mg 
stearate 1        25 0.49  5 7.5 
Lamotrigine 25 Mannitol 45.5        PVPP 3.75    
Mg 
stearate 0.75        25 0.46  5 6.12 
Lamotrigine 25 Mannitol 46.5        PVPP 2.5    
Mg 
stearate 0.75        10 1.7  5 3.99 
Lamotrigine 25 Mannitol 45.5        PVPP 3.75    
Mg 
stearate 0.75        25 0.51  5 8.1 
Clozapine 12.5 Mannitol 94.6 MCC 21     
CMS-
Na 11.2    
Mg 
stearate 0.7        31 0.68  8.5 14.6 
Clozapine 12.5 Mannitol 39.9 MCC 21     
CMS-
Na 11.2    
Mg 
stearate 0.7    
2-hydroxypropyl-β-
cyclodextrin 54.7 32 0.63  8.5 15.3 
Tramadol 50 Mannitol 172        PVPP 18    
Mg 
stearate 2 Aerosil  10     31 0.55  9 47 
Tramadol 50 Mannitol 166        PVPP 18    
Mg 
stearate 2 Aerosil  10     32 0.69  9 34 
Tramadol 50 Mannitol 172        PVPP 12    
Mg 
stearate 2 Aerosil  2     34 0.58  9 72 
Tramadol 50 Mannitol 178        PVPP 18    
Mg 
stearate 2 Aerosil  2     33 0.62  9 61 
Sildenafil 29.8 Mannitol 251.2        PVPP 13    
Mg 
stearate 3 Aerosil  0     52 0.19  10 25 
Sildenafil 29.8 Mannitol 236.2        PVPP 13    
Mg 
stearate 3 Aerosil  0     40 0.3  10 26 
Sildenafil 29.8 Mannitol 221.2        PVPP 13    
Mg 
stearate 3 Aerosil  0     35 0.41  10 25 
Sildenafil 29.8 Mannitol 206.2        PVPP 13    
Mg 
stearate 3 Aerosil  0     30 0.49  10 26 
Sildenafil 29.8 Mannitol 205.5        PVPP 13    
Mg 
stearate 3 Aerosil  0.75     32 0.46  10 27 
Sildenafil 29.8 Mannitol 204.7        PVPP 13    
Mg 
stearate 3 Aerosil  1.5     35 0.33  10 26 
Sildenafil 29.8 Mannitol 203.5        PVPP 13    
Mg 
stearate 3 Aerosil  2.25     33 0.3  10 27 
Ondansetron 8 Mannitol 22.5 MCC 18.87     PVPP 3.75    Aerosil  0.75        29 0.44 2.6 5.5 8.53 
Ondansetron 8 Mannitol 22.5 MCC 15.12     PVPP 7.5    Aerosil  0.75        22 0.38 2.57 5.5 10.17 
Ondansetron 8 Mannitol 22.5 MCC 11.37     PVPP 11.25    Aerosil  0.75        27 0.4 2.77 5.5 7.33 
Ondansetron 8 Mannitol 22.5 MCC 18.87     PVPP 3.75    Aerosil  0.75        26 0.53 2.72 5.5 6 
Ondansetron 8 Mannitol 22.5 MCC 15.12     PVPP 7.5    Aerosil  0.75        25 0.48 2.74 5.5 11.17 
Ondansetron 8 Mannitol 22.5 MCC 11.37     PVPP 11.25    Aerosil  0.75        23 0.59 2.83 5.5 7.17 
Ondansetron 8 Mannitol 22.5 MCC 18.87     PVPP 3.75    Aerosil  0.75        25 0.37 2.67 5.5 7 
Ondansetron 8 Mannitol 22.5 MCC 18.87     PVPP 3.75    Aerosil  0.75        28 0.49 2.68 5.5 28.5 
Ondansetron 8 Mannitol 22.5 MCC 15.12     PVPP 7.5    Aerosil  0.75        24 0.54 2.67 5.5 16.33 
Ondansetron 8 Mannitol 22.5 MCC 11.37     PVPP 11.25    Aerosil  0.75        24 0.62 2.66 5.5 26 
Ondansetron 8 Mannitol 22.5 MCC 21.87     PVPP 0.75    Aerosil  0.75        23 0.55 2.54 5.5 33 
Ondansetron 8 Mannitol 22.5 MCC 20.37     PVPP 2.25    Aerosil  0.75        25 0.46 2.46 5.5 21.17 
Ondansetron 8 Mannitol 22.5 MCC 18.87     PVPP 3.75    Aerosil  0.75        25 0.39 2.7 5.5 15.33 
Ondansetron 8 Mannitol 22.5 MCC 18.87     PVPP 3.75    Aerosil  0.75        27 0.29 2.54 5.5 15.67 
Ondansetron 8 Mannitol 22.5 MCC 17     PVPP 5.63    Aerosil  0.75        26 0.33 2.62 5.5 13.67 
Diclofenac 
sodium 50 MCC 10 
Lacto
se 131           Aerosil  5 
Mg 
stearate 4     55 0.68   8.5 
Fenoverine 100 Mannitol 93.75 MCC 37.5     CC-Na 10    Aerosil  2.5 
Mg 
stearate 1.25     30  5.5 8 70 
Fenoverine 100 Mannitol 88.75 MCC 37.5     CC-Na 15    Aerosil  2.5 
Mg 
stearate 1.25     27  5.5 8 55 
Fenoverine 100 Mannitol 83.75 MCC 37.5     CC-Na 20    Aerosil  2.5 
Mg 
stearate 1.25     25  5.5 8 40 
Fenoverine 100 Mannitol 93.75 MCC 37.5     PVPP 10    Aerosil  2.5 
Mg 
stearate 1.25     24  5.5 8 21 
Fenoverine 100 Mannitol 88.75 MCC 37.5     PVPP 15    Aerosil  2.5 
Mg 
stearate 1.25     24  5.6 8 19 
Fenoverine 100 Mannitol 83.75 MCC 37.5     PVPP 20    Aerosil  2.5 
Mg 
stearate 1.25     23  5.5 8 18 
Fenoverine 100 Mannitol 93.75 MCC 37.5     
CMS-
Na 10    Aerosil  2.5 
Mg 
stearate 1.25     25  5.6 8 37 
Fenoverine 100 Mannitol 88.75 MCC 37.5     
CMS-
Na 15    Aerosil  2.5 
Mg 
stearate 1.25     26  5.4 8 30 
Fenoverine 100 Mannitol 83.75 MCC 37.5     
CMS-
Na 20     Aerosil  2.5 
Mg 
stearate 1.25     25   5.6 8 31 
Table 2 The accuracies of OFDT on training, testing, and final testing sets 
Network 
Training Set  
(%) 
Validation Set  
(%) 
Testing Set  
(%) 
ANN 85.60 80.00 75.00 
DNN 85.60 85.00 80.00 
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